BUTANE-1,2,3-TRIOL DERIVATIVES, PROCESSES FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Abstract: The compounds represented by the formula (I) and the formula (II); These compounds are useful as an antihypertensive agent.

Description: Butane-1,2,3-triol derivatives, processes for preparing the same and pharmaceutical utical ccmpositions containing the same. The present invention relates to novel butane-1,2,3-triol derivatives having excellent antihypertensive activity, to processes for the preparation of the novel compounds as well as to pharmaceutical compOsitions containing said compounds. It is known that 1 -0-alkyl-2-0-acetyl-sn-glycero-3-phosphoryl- choline (Platelet Activating Factor (PAF)) has a strong platelet aggregation activity, hypotensive activity and bronchoconstrictive activity. The alkyl group analogues substituted at the 1-0-position and the acyl group analogues at the 2-0-position have been investigated for a long period, and a variety of papers have been reported. (Protein, Nucleic Acid and Enzyme, Vol. 27, No. 10, pp. 1342-47, 1982 and Japanese Kokai Tokkyo Koho JP 83013592). 1-0-alkyl-2-0-acetyl-sn-glycero-3-phosphorylcholine has a good antihypertensive activity, but also a strong platelet aggregation activity and, therefore, cannot be acceptable as an antihypertensive agent. The inventors of this application have been interested in and paid a great attention to the hypotensive activity of PAF and have carried out intensive investigations to find a favorable compound having only hypotensive activity and showing much less platelet aggregation activity from the synthetic glycerophosphorylcholine derivatives. The present invention satisfies the ahovementioned features of the selective activities and provides the highly potential biologically active compound having high hypotensive activity and much less platelet aggregation activity. It was found that the cccpounds represented by the formula (I) and the formula (II) EMI1.1 have excellent hypotensive activity and much less platelet aggregation activity and may be used as acceptable antihypertensive agents. Therefore, it is an object of the present invention to provide the novel compounds having the formulae (I) and (II). It is another object of the invention to provide a process for the preparation of the compound having the formula (I) which prises acetylating a compound having the formula (III) EMI2.1 in an organic solvent in the presence of base. It is still another object of this invention to provide a pro- cess for the preparation of the conpc1nd of the formula (II) which comprises acetylating a compOund of the formula (IV): EMI2.2 in an organic solvent in the presence of base. A further object of the invention is to provide pharmaceutical compositions having antihypertensive activity containing a compound having the formula (I) or (II) together with a pharmaceutically acceptable carrier. The foregoing and other objects of the present invention will be elucidated in the following description. Detailed Description of Preferred Embodiments In accordance with the present invention, the novel compound of the formula (I) is produced by acetylating a compound of the formula (III) in an organic solvent in the presence of base. In accordance with the present invention, the novel compound of the formula (II) is produced by a acetylating a compound of the formula (IV) in an organic solvent in the presence of base. Acetic anhydride or acetyl chloride is suitable as acetylating agent. The base may be an ordinary base such as pyridine, triethylamine and the like. The solvents used in this invention may be an inert solvent such as chloroform and the like, but if necessary the acetylating agent or the base that is used in the process of the present invention can be used as a solvent. The acetylation in the process of the present invention is carried out at the temperature ranging from the roan temperature to the boiling point of the solvent used, preferably under the milder condition for the period of about 30 minutes to several hours. After the reaction is completed, the solvent and the base and the like used are removed, and then the resulting mixture is purified by a column chromatography to yield the desired compound. The chemical structures are determined by measuring IR, NMR and mass spectra etc. It is noted that the compounds having the formula (I) or (II) may be prepared in a way known for analogous compounds. The starting materials, which are novel compounds, represented by the formula (III) and the formula (EV) can be prepared, for example, by the process of the reaction scheme mentioned below. EMI3.1 EMI4.1 The following examples illustrate the practice of the invention, but should not be interpreted as limiting the invention. Example 1: Preparation of (2s , 3S ) - 1 - ( 2-trimethylatnDnioethyl ) phosphoryl-2- acetoxy-3-hexadecyloxybutane (Compound 1) 1 ml of acetic anhydride was added to a solution of 134 mg of (2S,3S)-1-(2-trimethylammonioethyl)phosphoryl-3-hexadecyloxybutan- 2-ol in 2 ml of dry pyridine, and the resulting mixture was stirred for three hours at 60 C. The solvent was removed at 60 C and the residue was purified by silica gel column chromatography (chloroform:methanol:water = 65:35:6) to yield 112 mg of the objective compound in form of white wax having a melting point of 222 C to 230 C and the following characteristics: specific rotation (&alpha;)D21 1.11 (C 1.80, CHCl3:CH3OH = = 1:1), FAB -MS M/e 538 (M+ + 1) BFD2 (90 MHz, CDCl3:CD3OD = 4:1, TMS, # 0.88 (t, J=7Hz, 3H), 1.16 (d, J=6.8Hz, 3H), 1.26 (s, 26B), 1.45-1.70 (m, 2H), 2.08 (s,3H), 3.26 (s, 9H), 3.32-3.85 (m, 5H), 3.86-4.46 (m, 4H), 4.90-5.15 (m, 1H): IR (KBr, cm1); 3420, 2920, 2840, 1732, 1465, 1235 Example 2: : Preparation of (2S,3S)-1-(2-trLmethylammcnioethylWpbospboryl-2-ace- toxy-3-hexadecyloxybutane (Capound 2) 1 ml of acetic anhydride was added to a solution of 142 mg of (2S,3S)-1-(2-trimethylammonioethyl)phospheryl-3-hexadecyloxybutan- 2-ol in 2 ml of dry pyridine and the mixture was stirred for 3 hours at a temperature of 60"C and concentrated in vacuum to obtain the residue. The resulting residue was purified by a silica gel column chranatograph (chloroform:methanol:water = 65:35:6) to yield 109 mg of the objective compound in form of white wax, having a melting point of 232 CC to 240"C and the following characteristics: specific rotation; (0()21 7.03 (C 1.80, CHCl3:CH30H = 1:1) FAB-MS M/e 538 (M+ +1) NMR ( 90 MHz, CDC13 : CD30D = 3:1, TMS, J (ppm)); 0.88 (t, J=7HZ, 3H), 1.22 (d, J=6.3HZ, 3H), 1.26 (s, 26H), 1.45-1.70 (m,2H) 2.08 (s, 3H), 3.24 (s, 9H), 3.34-3.90 (m, 5H), 3.88-4.448 (m, 4H), 4.90-5.15 (m,1H), IR (KBr, cm1); 3420, 2920, 2840, 1732, 1465, 1235 Activity of the inventive compounds - the result of biological tests (1) Hypotensive activity Male Wistar rats weighing about 400 g were anesthetized with sodium pentobarbital (60 mg/kg, i.p.). The left femoral vein and the femoral artery were canulated for drug administration and blood pressure monitoring, respectively. The change of the blood pressure was measured by means of a pressure transducer and recorded on the polygraph. Each of the test compounds (which was dissolved in physiological saline or suspended with 2 % Tween 80 physiological saline solution) was injected into the left femoral vein through the canula. The results are shown in Table 1. TABLE 1 Dose Max. fall Fall in blood pressure after the ( g/kg) in blood injection (%) press. (%) 1 min. 2 min. 3 min. 5 min. 10 min. 5000 70 70 69 69 Com- 500 72 63 72 49 60 69 pound 1 50 59 49 47 47 49 59 5 48 19 10 10 10 10 5000 70 52 59 61 65 69 Com- 5QQ 50 39 46 36 35 24 pound 2 50 49 31 16 6 5 4 5 33 17 -4 -4 -4 -4 PAF 1.5 52 52 52 49 42 37 0.5 52 48 15 5 0 Fall in blood pressure after the injection (8) 15 min. 20 min. 30 min. 40 min. 57 49 43 33 6 68 70 70 70 20 19 17 16 5 (2) Platelet aggregating activity After t4C-labelled serotonin was incubated with a rabbit platelet-rich plasma (PRP) in accordance with the method dis closed in "Journal of Clinical Investigation, vol. 67, 903 (1981)" the test compounds were added to the serotonin in corporated PEP, and the activity thereof was measured by the amount of 50 8 release of serotonin. Ihe results are shown in Table 2. TABLE 2 Concentration of the test compound to induce 50 e release of serotinin (M) PAF - 10-9 Compound 1 1.8 x 10-6 Compound 2 - (release of serotonin cannot be measured until 10-6 M)

Claims: CLAIMS 1. A compound represented by the formula (I) or the formula (11) EMI7.1 2. A process for the preparation of the compound having the formula I which comprises acetylating the compound having the formula (III) EMI7.2 3. A process for the preparation of the compound having the formula (II) which comprises acetylating the compound having the formula (IV) EMI7.3 4. Pharmaceutical composition having antihypertensive activity, characterized in that it contains a coopand having the formula (I) or (II) together with a pharmaceutically acceptable carrier. 5. A compound represented by the formula (III) or (IV), suitable as starting material for the process according to claim 2 or 3 respectively.

Inventors: FUJITA, KAGARI, OHNO, MASAJI, SHIRAIWA, MASAFUMI
Applicants: TEIKOKU HORMONE MFG. CO., LTD.
Application year: 1986
Main classification: C07F9
IPC codes: C07F9